InvestLog
ORKA Oruka Therapeutics, Inc. logo

ORKA Oruka Therapeutics, Inc.

Healthcare
$60.61+3.27%ClosedMarket Cap: $2.27B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.87

P/S

0.00

EV/EBITDA

-17.69

DCF Value

$0.90

FCF Yield

-4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-26.0%

ROA

-23.0%

ROIC

-27.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-31.8M$—
Q4 null$0.00$-29.6M$—
FY null$0.00$-105.4M$—
Q3 null$0.00$-30.3M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$136.38

Target (Median)

$135.50

Target Range

$75.00 - $200.00

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-18
BTIGBuy
2026-05-14
BarclaysOverweight
2026-04-28
UBSBuy
2026-04-28
WedbushOutperform
2026-04-15

Trading Activity

Insider Trades

View All
Dambkowski Carldirector
SellFri May 22
Dambkowski Carldirector
SellFri May 22
Dambkowski Carldirector
SellFri May 22
Dambkowski Carldirector
SellFri May 22
Dambkowski Carldirector
SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

-0.25

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Peers

ANAB logoANABBBOT logoBBOTKOD logoKODMNMD logoMNMDNRIX logoNRIXOCS logoOCSPHAT logoPHATRAPP logoRAPPURGN logoURGNXNCR logoXNCR